Eli Lilly created Mounjaro, the brand name for the diabetes medicine tirzepatide.
Eli Lilly and Company was founded in Indianapolis in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Union army veteran. The company emphasized manufacturing medicines with consistent quality at a time when drug composition could vary widely.
Mounjaro received U.S. Food and Drug Administration approval in 2022 for adults with type 2 diabetes. Tirzepatide acts on GIP and GLP-1 hormone pathways, helping regulate blood sugar and, in clinical studies, producing substantial weight loss. The related obesity treatment is marketed in the United States as Zepbound.
Mounjaro and Zepbound are not the same brand indication, although they contain the same active ingredient. Eli Lilly’s valuation has been strongly influenced by demand and expectations for this class of medicines, but market capitalization remains separate from drug sales or profit.